For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

Even when diagnosed at an advanced stage, most prostate cancers respond well to treatment. The first line of treatment is often hormone therapy, which is very good at slowing or stopping the cancer — ...

Early-stage prostate cancer is very treatable with surgery and radiation therapy. Once the cancer spreads, it becomes harder to stop. Late-stage prostate cancer treatments like chemotherapy and ...

Prostate cancer treatment, particularly hormone therapy, significantly disrupts sleep, leading to fatigue and reduced daytime ...

Nigeria records over 18,000 new prostate cancer cases annually, accounting for the highest cancer burden among men in the country.